IMPROVING PERFORMANCE OF MULTI-ATTRUBUTE METHOD ASSAYS USING AN LC-MS WITH A NOVEL INERT FLUDIC PATHWAY

Importance of the Topic

The Peptide Multi-Attribute Method (MAM) is a pivotal LC-MS technique for direct quantification of product-related and critical quality attributes in biotherapeutic proteins. By monitoring modifications such as deamidation, oxidation, and glycosylation, MAM supports robust quality control and regulatory compliance, enabling comprehensive characterization of complex biologics.

Study Objectives and Overview

This study evaluates how an inert fluidic pathway in an LC-MS system improves MAM assay performance. The specific aims were to reduce peptide losses on metal surfaces, enhance recovery of acidic and metal-sensitive peptides, and extend dynamic range and reproducibility of critical quality attribute measurements.

Methodology and Instrumentation

Peptide Digest Preparation:

• Waters NISTmAb tryptic digestion standard in 0.1% formic acid
• On-column loads from 0.1 µg to 2.0 µg per injection

Chromatography:

• Comparison of conventional BioAccord System versus BioAccord with ACQUITY Premier UPLC
• Columns: ACQUITY Peptide CSH C18 (130Å, 1.7 µm, 2.1 × 150 mm) with standard or MaxPeak High Performance Surfaces (HPS)
• Gradient: 78 min linear 1–35% acetonitrile in 0.1% formic acid

Mass Spectrometry:

• Electrospray ionization in positive mode (ESI+)
• Data‐independent acquisition (MSE) across m/z 50–2000 with fragmentation

Data Processing:

• Waters_connect UNIFI, MS-Toolkit, and Peptide MAM applications for peak detection, quantification, and confirmatory fragmentation analysis

Main Results and Discussion

Improved Peptide Recovery:

• Acidic peptides prone to adsorption on metal surfaces showed significantly higher recovery using the Premier HPS pathway
• Deamidated and succinimide variants of the PENNYK peptide exhibited sharper peaks and greater area response

Extended Dynamic Range and Consistency:

• Accurate quantification of both high and low abundance attributes across three orders of magnitude
• Stable % modification measurements above 0.2 µg load, with low relative standard deviations (RSDs <1%)

Enhanced Fragmentation Quality:

• Clearer MS/MS spectra for metal-sensitive peptide variants, improving confidence in structural confirmation

Reproducibility:

• Across five replicates, the ACQUITY Premier system reduced variability in % modification determinations compared to conventional hardware

Benefits and Practical Applications

By minimizing analyte loss on metal components, the inert fluidic pathway delivers:

• Greater assay sensitivity and quantification accuracy for critical quality attributes
• Flexible loading options without sacrificing precision
• Single-run monitoring of diverse modifications ranging from glycoforms to oxidative variants

These improvements support quality control in biopharmaceutical development and manufacturing, ensuring reliable product characterization.

Future Trends and Applications

Ongoing developments may include:

• Broader adoption of inert pathways in LC platforms for host-cell protein and peptide impurity analysis
• Integration with advanced informatics and machine learning for automated peak annotation and trend analysis
• Expansion of MAM workflows to next-generation biologics, including fusion proteins and bispecific antibodies

Conclusion

The integration of an inert fluidic pathway via ACQUITY Premier with MaxPeak HPS technology significantly enhances MAM assay performance. Improved peptide recovery, extended dynamic range, superior fragmentation data, and high reproducibility establish this approach as a valuable advancement for quality attribute monitoring in biotherapeutic analysis.